Mosaic variegated aneuploidy syndrome 2 with biallelic novel CEP57 splice site variation in Indian siblings: Expanding the clinical and molecular spectrum

Clin Genet. 2023 Apr;103(4):478-483. doi: 10.1111/cge.14297. Epub 2023 Jan 23.

Abstract

Mosaic variegated aneuploidy syndrome 2 (MVA2) (MIM# 614114) is a rare autosomal recessive condition caused by biallelic loss of function variants in the CEP57 gene. MVA2 is characterized by a variable phenotype ranging from poor growth to facial dysmorphism, short stature and congenital heart defects. Only 11 families and 5 pathogenic variants of MVA2 have been described so far. Intragenic duplication of 11 nucleotides (c.915_925dup11) in homozygous or compound heterozygous state is the commonest genetic aberration (10/13). We describe the first Indian family with two siblings with a novel homozygous splice site variant (c.382+2T>C) in CEP57. Molecular characterization demonstrated skipping of exon 3 due to the variant with protein modeling predicting subsequent complete loss of function. This is the first report of a splice site variation in CEP57 leading to MVA2.

Keywords: Arnold-Chiari malformation; CEP57; centrosomal protein; growth retardation; mosaic variegated aneuploidy; radial ray defect; short stature.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aneuploidy
  • Chromosome Disorders* / genetics
  • Humans
  • Microtubule-Associated Proteins / genetics
  • Mosaicism
  • Mutation
  • Nuclear Proteins / genetics
  • Siblings*
  • Syndrome

Substances

  • CEP57 protein, human
  • Microtubule-Associated Proteins
  • Nuclear Proteins

Supplementary concepts

  • Mosaic variegated aneuploidy syndrome